GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
72.79
+9.97 (15.87%)
At close: Oct 8, 2025, 4:00 PM EDT
73.00
+0.21 (0.29%)
After-hours: Oct 8, 2025, 7:58 PM EDT
GRAIL Revenue
GRAIL had revenue of $35.54M in the quarter ending June 30, 2025, with 11.18% growth. This brings the company's revenue in the last twelve months to $134.29M, up 22.37% year-over-year. In the year 2024, GRAIL had annual revenue of $125.60M with 34.90% growth.
Revenue (ttm)
$134.29M
Revenue Growth
+22.37%
P/S Ratio
18.38
Revenue / Employee
$134,285
Employees
1,000
Market Cap
2.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 125.60M | 32.49M | 34.90% |
| Dec 31, 2023 | 93.11M | 37.56M | 67.61% |
| Jan 1, 2023 | 55.55M | 40.94M | 280.17% |
| Jan 2, 2022 | 14.61M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
GRAL News
- 8 days ago - Grail: A Speculative Buy - Seeking Alpha
- 15 days ago - GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC - PRNewsWire
- 19 days ago - Sun World International and Pairwise Launch Strategic Partnership to Develop a Holy Grail of Produce – the Pitless Cherry - GlobeNewsWire
- 4 weeks ago - GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum - PRNewsWire
- 4 weeks ago - GRAIL, Inc. (GRAL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 5 weeks ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 6 weeks ago - GRAIL to Present at Morgan Stanley 23rd Annual Global Healthcare Conference - PRNewsWire